In this issue:
RCT representativeness and outcomes in real-world patients
Outpatient autologous stem cell transplants for MM
Optimal sequence of daratumumab and elotuzumab in RRMM
Outcomes of patients with nonsecretory MM
Therapeutic activity of anti-BCMA BiTE molecule AMG 420 in RRMM
Clinical application of BCMA peptide-engineered nanoparticles
Factors predicting outcome for myeloma patients at different ages
Bortezomib therapy pre- and post-transplant in high-risk MM
Cereblon gene polymorphisms predict response to lenalidomide
The kynurenine pathway as a novel target for anti-MM therapeutics
Please login below to download this issue (PDF)